Literature DB >> 19574923

When statin therapy stops: implications for the patient.

Stella S Daskalopoulou1.   

Abstract

PURPOSE OF REVIEW: To discuss recent findings on the implications of statin discontinuation. RECENT
FINDINGS: The beneficial effects of statins in decreasing inflammatory markers, cardiovascular events, cardiovascular mortality, and all-cause mortality in patients with and without a history of cardiovascular disease have been underscored in past and recent studies. However, patients often do not adhere to their statin therapy. Discontinuation rates, though improved over time, remain high not only in primary but also in secondary prevention patients in the clinical practice. Recent studies have found that discontinuing statins, particularly after acute events (e.g. acute myocardial infarction or stroke), has a harmful effect on cardiovascular outcomes and all-cause mortality; patients who discontinued their statin therapy had worse outcomes than those who were never prescribed statins. This could be attributed to a biological rebound phenomenon.
SUMMARY: Statin therapy has a number of beneficial effects on patient outcomes and should be prescribed according to current cardiovascular disease guidelines. Importantly, statin discontinuation is associated with harmful outcomes. Clinicians should become more aware of these effects and counsel their patients to adhere to their statin therapy. Current evidence suggests that, unless contraindicated, statins should not be discontinued, especially after an acute vascular event.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574923     DOI: 10.1097/HCO.0b013e32832ebf92

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  7 in total

1.  Developing the evidence base for palliative care: formation of the Palliative Care Research Cooperative and its first trial.

Authors:  Thomas W LeBlanc; Jean S Kutner; Danielle Ko; Jane L Wheeler; Janet Bull; Amy P Abernethy
Journal:  Hosp Pract (1995)       Date:  2010

2.  Which statin worked best to achieve lipid level targets in a European registry? A post-hoc analysis of the EUROASPIRE III for coronary heart disease patients.

Authors:  Fahad Alnouri; David Wood; Kornelia Kotseva; Mohamed E A Ibrahim
Journal:  J Saudi Heart Assoc       Date:  2014-05-04

3.  Statin withdrawal beyond acute phase affected outcome of thrombolytic stroke patients: an observational retrospective study.

Authors:  Lu-Sha Tong; Hai-Tao Hu; Sheng Zhang; Shen-Qiang Yan; Min Lou
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

4.  Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol.

Authors:  Shi-You Jiang; Hui Li; Jing-Jie Tang; Jie Wang; Jie Luo; Bing Liu; Jin-Kai Wang; Xiong-Jie Shi; Hai-Wei Cui; Jie Tang; Fan Yang; Wei Qi; Wen-Wei Qiu; Bao-Liang Song
Journal:  Nat Commun       Date:  2018-12-03       Impact factor: 14.919

5.  Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study.

Authors:  Seung-Hwan Lee; Hyuk-Sang Kwon; Yong-Moon Park; Seung-Hyun Ko; Yoon-Hee Choi; Kun-Ho Yoon; Yu-Bae Ahn
Journal:  Diabetes Metab J       Date:  2014-02-19       Impact factor: 5.376

6.  Discontinuation of simvastatin leads to a rebound phenomenon and results in immediate peri-implant bone loss.

Authors:  Xianqi Li; Feng Wu; Yiming Zhang; Jing Yang; Atsushi Shinohara; Hideaki Kagami
Journal:  Clin Exp Dent Res       Date:  2016-03-18

7.  HSF1 Regulates Mevalonate and Cholesterol Biosynthesis Pathways.

Authors:  Hyeji Kang; Taerim Oh; Young Yil Bahk; Geon-Hee Kim; Sang-Yeon Kan; Dong Hoon Shin; Ji Hyung Kim; Ji-Hong Lim
Journal:  Cancers (Basel)       Date:  2019-09-13       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.